A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

United States

Florida Cancer Specialists, Sarasota, Florida

Moffitt Cancer Center, Tampa, Florida

NEXT Oncology, San Antonio, Texas

NEXT Virginia, Fairfax, Virginia